Prognostic value of [18F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies

[1] Ostrom QT(2016)CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013 Neuro-Oncol 18 v1-v75

[2] Gittleman H(2018)The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades Neuro-Oncol. 20 687-694

[3] Xu J(1998)Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d’étude des Leucénies et Autres Maladies du Sang (GOELAMS) Am J Clin Pathol 110 607-612

[4] Mendez JS(2017)International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017) Ann Oncol 28 1436-1447

[5] Ostrom QT(2014)Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification J Clin Oncol 32 3059-3068

[6] Gittleman H(2018)18F-FDG PET/CT in primary brain lymphoma J Neuro-Oncol 136 577-583

[7] Camilleri-Broët S(2018)Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma Ann Nucl Med 32 532-541

[8] Martin A(2017)Primary CNS lymphoma J Clin Oncol 35 2410-2418

[9] Moreau A(2017)Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma Cancer Discov 7 1018-1029

[10] Younes A(2019)Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma Blood. 133 436-445

[1] Ostrom QT(2016)CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013 Neuro-Oncol 18 v1-v75

[2] Gittleman H(2018)The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades Neuro-Oncol. 20 687-694

[3] Xu J(1998)Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d’étude des Leucénies et Autres Maladies du Sang (GOELAMS) Am J Clin Pathol 110 607-612

[4] Mendez JS(2017)International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017) Ann Oncol 28 1436-1447

[5] Ostrom QT(2014)Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification J Clin Oncol 32 3059-3068

[6] Gittleman H(2018)18F-FDG PET/CT in primary brain lymphoma J Neuro-Oncol 136 577-583

[7] Camilleri-Broët S(2018)Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma Ann Nucl Med 32 532-541

[8] Martin A(2017)Primary CNS lymphoma J Clin Oncol 35 2410-2418

[9] Moreau A(2017)Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma Cancer Discov 7 1018-1029

[10] Younes A(2019)Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma Blood. 133 436-445